Electromed, Inc. Files Q2 FY2025 10-Q Report

TL;DR

Electromed's Q2 FY25 10-Q is in. Check financials.

AI Summary

Electromed, Inc. filed its 10-Q for the period ending December 31, 2024. The filing covers the second quarter of their fiscal year 2025. Key financial data and business operations for this period are detailed within the report.

Why It Matters

This 10-Q filing provides investors and analysts with a detailed look at Electromed's financial performance and operational status for the second quarter of fiscal year 2025, crucial for understanding the company's trajectory.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing standard financial disclosures.

Key Numbers

• 2024-12-31 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
• 2025-02-11 — Filing Date (The date Electromed, Inc. submitted this 10-Q to the SEC.)

Key Players & Entities

• Electromed, Inc. (company) — Filer of the 10-Q report
• 2024-12-31 (date) — End of the reporting period
• 2025-02-11 (date) — Date the filing was made

FAQ

Key Financial Figures

• $0.01 — ection 12(b) of the Act: Common Stock, $0.01 par value ELMD NYSE American LLC
• $24,130,000 — redit losses, as of June 30, 2023, were $24,130,000. Six Months Ended December 31, 2024

Filing Documents

• elmd250096_10q.htm (10-Q) — 502KB
• elmd250096_ex31-1.htm (EX-31.1) — 8KB
• elmd250096_ex31-2.htm (EX-31.2) — 8KB
• elmd250096_ex32-1.htm (EX-32.1) — 3KB
• elmd250096_ex32-2.htm (EX-32.2) — 3KB
• 0000897101-25-000089.txt ( ) — 3193KB
• elmd-20241231.xsd (EX-101.SCH) — 25KB
• elmd-20241231_cal.xml (EX-101.CAL) — 41KB
• elmd-20241231_def.xml (EX-101.DEF) — 72KB
• elmd-20241231_lab.xml (EX-101.LAB) — 269KB
• elmd-20241231_pre.xml (EX-101.PRE) — 203KB
• elmd250096_10q_htm.xml (XML) — 359KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 1

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 11

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 16

Controls and Procedures

Item 4. Controls and Procedures 16

– OTHER INFORMATION

PART II – OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 16

Risk Factors

Item 1A. Risk Factors. 16

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 17

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 17

Other Information

Item 5. Other Information 17

Exhibits

Item 6. Exhibits 18

– FINANCIAL

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Electromed, Inc. Condensed Balance Sheets December 31, 2024 June 30, 2024 (Unaudited) Assets Current Assets Cash and cash equivalents $ 16,235,000 $ 16,080,000 Accounts receivable (net of allowances for credit losses of $ 45,000 ) 22,775,000 23,333,000 Contract assets 997,000 719,000 Inventories 3,081,000 3,712,000 Income taxes receivable 514,000 - Prepaid expenses and other current assets 587,000 329,000 Total current assets 44,189,000 44,173,000 Property and equipment, net 5,216,000 5,165,000 Finite-life intangible assets, net 609,000 657,000 Other assets 108,000 87,000 Deferred income taxes 2,152,000 2,152,000 Total assets $ 52,274,000 $ 52,234,000 Liabilities and Shareholders' Equity Current Liabilities Accounts payable $ 1,506,000 $ 1,010,000 Accrued compensation 3,623,000 3,893,000 Income tax payable - 277,000 Warranty reserve 1,599,000 1,567,000 Other accrued liabilities 1,939,000 930,000 Total current liabilities 8,667,000 7,677,000 Other long-term liabilities 4,000 12,000 Total liabilities 8,671,000 7,689,000 Shareholders' Equity Common stock, $ 0.01 par value per share, 13,000,000 shares authorized; 8,556,844 and 8,637,883 shares issued and outstanding, as of December 31, 2024 and June 30, 2024, respectively 86,000 87,000 Additional paid-in capital 20,940,000 20,790,000 Retained earnings 22,577,000 23,668,000 Total shareholders' equity 43,603,000 44,545,000 Total liabilities and shareholders' equity $ 52,274,000 $ 52,234,000 See Notes to Condensed Financial Statements (Unaudited). 1 Electromed, Inc. Condensed Statements of Operations (Unaudited) Three Months Ended Six Months Ended December 31, December 31, 2024 2023 2024 2023 Net revenues $ 16,255,000 $ 13,689,000 $ 30,923,000 $ 26,013,000 Cost of revenues 3,628,000 3,144,000 6,805,000 5,970,000 Gross profit 12,627,000 10,545,00

Financial Statements

Financial Statements (Unaudited) Note 1. Interim Financial Reporting Nature of business: Electromed, Inc. (the "Company") develops, manufactures and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation ("HFCWO") therapy in pulmonary care for patients of all ages. The Company markets its products in the U.S. to the homecare and hospital markets. The Company also sells internationally through distributors. Since its inception, the Company has operated in a single industry segment: developing, manufacturing, and marketing medical equipment. Basis of presentation: The accompanying unaudited Condensed Financial Statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial statements and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, the accompanying unaudited Condensed Financial Statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024 ("fiscal 2024"). A summary of the Company's significant accounting policies and estimates: Our significant accounting policies are detailed in Note 1. Nature of Business and Summary of Significant Accounting Policies of the Annual Report on Form 10-K for the year ended June 30, 2024. There have been no significant changes to these policies that have had a material impact on the Unaudi

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Financial 30, 2024 ("fiscal 2024"). Overview Electromed, Inc. ("we," "our," "us," "Electromed" or the

View Full Filing

View this 10-Q filing on SEC EDGAR